天花疫苗(Bavarian Nordic A/S)(Smallpox vaccine(Bavarian Nordic A/S)) - 在研适应症：猴痘，天花，牛痘病毒感染_专利_临床

概要

基本信息

药物类型

减毒活疫苗、预防性疫苗

别名

modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus、modified vaccinia Ankara virus、Modified Vaccinia Ankara-Bavarian Nordic

+ [11]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段批准上市

首次获批日期

欧盟 (2013-07-31),

猴痘天花牛痘病毒感染

最高研发阶段(中国)-

特殊审评紧急使用授权 (美国)

登录后查看时间轴

关联

35

项与天花疫苗(Bavarian Nordic A/S) 相关的临床试验

NCT05513313

/ Not yet recruitingN/A

Prospective Assessment of Myocarditis After Replication-Deficient Smallpox Immunization

This is a prospective observational phase IV study of a novel, replication-deficient smallpox vaccine that has been recently been approved by FDA. The purpose of this study is to determine if there are any abnormalities detected by electrocardiographic testing and/or blood tests within 35 days of receiving the second dose of smallpox vaccine either alone or co-administered with other vaccines that may/may not be suggestive of myopericarditis.

开始日期2029-03-01

申办/合作机构

Womack Army Medical Center

[+1]

NCT06839989

/ Not yet recruiting临床2期IIT

The Mpox Biology, Outcome, Transmission and Epidemiology Project - HIV Immunization and Vaccination Against Mpox EXposure Trial

This is an open-label, phase 2, immunogenicity and safety trial of the MVA-BN vaccine for the prevention of mpox in adults living with HIV with different level of CD4 counts in Kinshasa, DRC.
The study team aims to investigate whether the administration of 2 standard subcutaneous doses of the Modified Vaccinia Ankara of Bavarian Nordic (MVA-BN) vaccine given 28 days apart, is immunogenic and safe when administered to People Living with HIV (PLHIV) with different levels of CD4 counts in the Democratic Republic of the Congo (DRC).
Enrollment will be stratified according to three different subgroups based on CD4 counts assessed during visit 1A: <200 cells/µL; 200 to 499 cells/µL; ≥ 500 cells/µL. A total of 600 participants will be included in the trial, with 200 participants per subgroup.
All participants will be invited to 6 trial visits over a period of 7 months.
This study will take place in cooperation with the National Programme for the Fight against AIDS (PNLS), the 'Programme Elargi de Vaccination (PEV)' and the 'Institut National de Santé Publique (INSP)'. As part of the response to the current mpox epidemic in DRC, a large cohort of about 10,000 individuals living in Kinshasa will be vaccinated in this program. Vaccination will take place in the Centre Hospitalier Kabinda (CHK) and the Pakadjuma Health Centre. All people living with HIV (PLHIV) with the intention to be vaccinated in the CHK, will be asked for their willingness to participate in the MBOTE-HIVAX clinical trial until the sample size of 600 participants needed for this clinical trial is reached.

开始日期2025-05-01

申办/合作机构

MSF Medecins Sans Frontieres

NCT06844500

/ Not yet recruiting临床3期IIT

Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo

This Phase 3 open-label study aims to assess the safety and immune response of the MVA-BN mpox vaccine when administered subcutaneously to pregnant and postpartum women in the Democratic Republic of the Congo (DRC), a population at high risk of mpox infection. The study will be conducted in Boende, Tshuapa Province, DRC.
A total of 359 maternal participants, aged 16 to 35 and in their second or third trimester of pregnancy, will be enrolled. Participants will be randomly assigned to receive two subcutaneous doses of the MVA-BN vaccine, given 28 days apart, either during pregnancy (Maternal Group 1) or within 72 hours after delivery (Maternal Group 2). Additionally, pregnant women in any trimester who have been recently exposed to a confirmed mpox case will be enrolled in the post-exposure prophylaxis (PEP) arm (Maternal Group 3), receiving the vaccine as soon as possible after exposure-ideally within four days but up to 14 days if they remain asymptomatic.
The study will evaluate the safety, reactogenicity, and immune responses of vaccinated pregnant women compared to healthy adults in the POX-MVA-045 study (NCT06549530) through non-inferiority analyses. Participants will be monitored for immunogenicity and safety for 13 months post-delivery, while neonates will be observed for safety over the same period. The trial will also compare outcomes between women vaccinated during pregnancy and those vaccinated postpartum, assess the transfer of maternal immunity to neonates, and explore correlations between maternal antibody levels in serum and breast milk.
This study seeks to provide strong evidence supporting the safety and immunogenicity of the MVA-BN mpox vaccine in pregnancy, contributing to global public health efforts to protect at-risk women and their infants in mpox-endemic regions.

开始日期2025-03-31

申办/合作机构

University of Antwerp

[+4]

100 项与天花疫苗(Bavarian Nordic A/S) 相关的临床结果

登录后查看更多信息

100 项与天花疫苗(Bavarian Nordic A/S) 相关的转化医学

登录后查看更多信息

100 项与天花疫苗(Bavarian Nordic A/S) 相关的专利（医药）

登录后查看更多信息

859

项与天花疫苗(Bavarian Nordic A/S) 相关的文献（医药）

2025-12-31·Virulence

Mpox: Global epidemic situation and countermeasures

Review

作者: Luo, Yinghua ; Jin, Chenghao ; Hou, Wenshuang ; Tang, Yanjun ; Wu, Nan ; Liu, Yanzhi ; Quan, Quan

Mpox, is a zoonotic disease caused by the monkeypox virus and is primarily endemic to Africa. As countries gradually stop smallpox vaccination, resistance to the smallpox virus is declining, increasing the risk of infection with mpox and other viruses. On 14 August 2024, the World Health Organization announced that the spread of mpox constituted a public health emergency of international concern. Mpox's transmission routes and symptoms are complex and pose new challenges to global health. Several vaccines (such as ACAM2000, JYNNEOS, LC16m8, and genetically engineered vaccines) and antiviral drugs (such as tecovirimat, brincidofovir, cidofovir, and varicella immunoglobulin intravenous injection) have been developed and marketed to prevent and control this disease. This review aims to introduce the epidemic situation, epidemiological characteristics, physiological and pathological characteristics, and preventive measures for mpox in detail, to provide a scientific basis for the prevention and control of mpox viruses worldwide.

2025-04-01·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Short-term evolution of Mpox-specific IgG and neutralizing antibodies among individuals undergoing MVA-BN vaccination

Article

作者: Chen, Kai-Hsiang ; Huang, Yu-Shan ; Chao, Tai-Ling ; Chen, Ling-Ya ; Li, Guei-Chi ; Chen, Yi-Chun ; Liu, Wen-Chun ; Liu, Wang-Da ; Chang, Hsi-Yen ; Chang, Sui-Yuan ; Yao, Yi ; Lin, Chia-Yi ; Chang, Lan-Hsin ; Wang, Jann-Tay ; Hung, Chien-Ching ; Chen, Yi-Ting ; Luo, Yu-Zhen ; Wu, Cheng-Hsin ; Hsu, Wei-Ting ; Chang, Shih-Chung ; Sun, Hsin-Yun ; Su, Yi-Ching ; Sheng, Wang-Huei ; Huang, Chun-Fu ; Lin, Chi-Ying ; Lin, Kuan-Yin ; Hsieh, Szu-Min ; Wu, Pei-Ying ; Chuang, Yu-Chung

OBJECTIVES:

The data on immune responses of individuals undergoing modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination are scarce. We aimed to compare Mpox virus-specific antibody and neutralizing antibody responses among people with and those without HIV receiving MVA-BN vaccines.

METHODS:

This prospective study enrolled participants undergoing two-dose MVA-BN vaccination to investigate seroresponses after vaccination. Blood samples were collected before and after each dose of vaccination for determinations of anti-A29 and anti-H3 IgG. Neutralization tests were conducted for samples tested positive for both anti-A29 and anti-H3 IgG.

RESULTS:

Overall, 441 participants undergoing two-dose MVA-BN vaccination were enrolled. Seroconversion for anti-A29 and anti-H3 IgG, respectively, after the second dose of vaccination was 18.2% and 61.2%, 10.9% and 65.0%, and 51.6% and 90.6% among people with HIV, people without HIV, and those who had had smallpox vaccination previously, respectively. About 20% of the participants with seroconversion lost seroresponses after a 7-month period of observation. None of the serum samples from vaccinated participants demonstrated neutralizing ability.

CONCLUSIONS:

Participants with previous smallpox vaccination had higher and more sustained antibody responses after receiving two doses of MVA-BN vaccines than those who had not undergone smallpox vaccination. More studies are warranted to assess the seroresponses to booster MVA-BN vaccination for vaccine nonresponders or those having lost seroresponses.

2025-03-13·Eurosurveillance

Case series of the first five human infections with monkeypox virus clade Ib and report on the public health response, United Kingdom, October to November 2024

Article

作者: Tunbridge, Anne ; Groves, Natalie ; Thomas, Sherine ; Padfield, Simon ; Rampling, Tommy ; Pullan, Steven ; Kliner, Merav ; Welfare, William ; Alonso, Alejandra ; Hughes, Gareth J ; Alvi, Muhammad Ibaad ; O’Hara, Geraldine ; Heinsbroek, Ellen ; Whittaker, Elizabeth ; Armstrong, Gillian ; Chand, Meera ; Dunning, Jake ; Hopkins, Susan ; Gallagher, Eileen ; Emmett, Hannah E ; Payne, Brendan AI ; Houlihan, Catherine F ; Belfield, Amy ; Beadsworth, Mike ; Gordon, N Claire

We report two importations of monkeypox virus clade Ib infection to the United Kingdom in 2024. The first was a traveller returning from Tanzania, Rwanda and Uganda, the second from Uganda. Both presented with fever and typical skin lesions; 147 contacts were followed up, 19 vaccinated with MVA-BN. Three household contacts of the first individual, including two children, became infected. These are the first reported autochthonous transmissions of clade Ib in Europe, and first paediatric cases outside the African continent.

347

项与天花疫苗(Bavarian Nordic A/S) 相关的新闻（医药）

2025-03-03

·Pharmaceutical Technology

EC approves Bavarian Nordic’s chikungunya vaccine marketing

The vaccine’s launch by the company in the main European markets is anticipated in the first half of 2025. Credit: Pormezz/Shutterstock. The European Commission (EC) has authorised the marketing of Bavarian Nordic’s Vimkunya – the first chikungunya vaccine approved in Europe for individuals as young as 12 years old. Vimkunya is a virus-like particle (VLP) single-dose vaccine tailored for active immunisation to prevent disease caused by the chikungunya virus. The authorisation is valid in all European Union member states and also in Liechtenstein, Norway and Iceland. The announcement follows US Food and Drug Administration (FDA) approval in February 2025. A marketing authorisation application was submitted by the company to the UK’s Medicines and Healthcare products Regulatory Agency, with UK approval anticipated in the first half of 2025. Bavarian Nordic CEO and president Paul Chaplin said: “We are highly encouraged by the European Commission’s accelerated decision to approve our chikungunya vaccine in Europe, which offers a differentiated profile for travellers, including those as young as 12 years. “As we expand our presence across Europe, this vaccine will help to further consolidate our leading position in travel vaccines, and we look forward to making the vaccine available in key markets during the first half of 2025.” The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the vaccine in January 2025, based on two Phase III clinical trial outcomes. These trials enrolled 3,500 healthy participants aged 12 and above. It demonstrated that the vaccine induced neutralising antibodies in up to 97.8% of vaccinated people within 21 days post-vaccination and showed a quick immune response from the first week. The vaccine’s mechanism of action involves inducing neutralising antibodies against chikungunya virus proteins, potentially offering protection from infection. In December 2024, the company signed a licence and manufacturing agreement with the Serum Institute of India for MVA-BN.

临床3期上市批准疫苗临床结果

2025-01-21

·生物制品圈

疫苗抗体反应持久性的机制

在疫苗学中，如何诱导持久的保护性免疫是一个主要挑战。通常认为，对感染的保护主要通过抗体实现，这些抗体能防止宿主细胞被感染。一些减毒活疫苗（如天花疫苗和黄热病疫苗）能诱导持久的抗体反应，这种反应可以持续终生；然而，在其他类型的疫苗中，包括季节性流感的灭活亚单位疫苗、百日咳疫苗、伤寒沙门菌疫苗、脑膜炎奈瑟菌疫苗，以及RTS,S疟疾疫苗和一些针对HIV的候选疫苗中，抗体反应的减弱现象已经被广泛记录。为什么有些疫苗能提供终生保护，而另一些疫苗只能保护几个月，这仍然是免疫学中的一大未解之谜。佐剂是疫苗中的一种成分，它能增强免疫反应的强度和持久性。在过去的70多年里，不溶性铝盐（alum）是唯一被批准的佐剂。然而，在过去的三十年中，被批准用于疫苗的佐剂数量显著增长。这些佐剂包括用于流感疫苗的油包水乳剂类佐剂（如MF59和AS03）、含有TLR4激动剂3-O-脱酰基-4'-单磷酰脂质A（MPL）的佐剂（如AS01和AS04，广泛用于呼吸道合胞病毒、带状疱疹和人乳头瘤病毒疫苗），TLR9激动剂CpG寡核苷酸（CpG 1018，用于乙肝疫苗HepB-CpG），以及最近应用于重组COVID疫苗和R21疟疾疫苗的皂苷基佐剂Matrix M。尽管佐剂技术取得了如此大的发展，但多数佐剂的分子机制仍然了解甚少。 2025年1月2日，斯坦福大学的Bali Pulendran 团队在Nature Immunology上发表题为System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans的文章。该研究通过系统疫苗学分析揭示了血小板和巨核细胞在增强疫苗抗体反应耐久性中的关键作用，并开发了一种基于转录特征的模型，可跨多种疫苗预测抗体反应的持久性。作者将50名健康志愿者（年龄21-45岁）随机分为两组，分别接种两剂次H5N1疫苗（间隔21天），其中34人接种了含AS03佐剂的疫苗，16人接种了不含佐剂的疫苗。通过采集外周血单个核细胞（PBMCs）样本，分析接种前后不同时间点的基因表达、免疫细胞激活、抗体水平和中和能力。结果显示含AS03佐剂的疫苗诱导了更强的早期转录响应、更高水平的中和抗体以及更快的T细胞和B细胞活化。不含佐剂组的免疫反应显著弱于含佐剂组，需要第二次接种才能达到较低水平的免疫激活。作者接下来通过转录组学和基因集富集分析，探索与抗体反应耐久性相关的分子特征。使用机器学习方法，在多种疫苗的临床试验数据中训练模型，预测抗体耐久性。验证模型的泛化能力，包括其他疫苗（如COVID-19 mRNA疫苗、疟疾疫苗等）中的应用。作者发现一种血小板活化和细胞粘附相关的基因模块（例如M196模块），可用于预测抗体反应的耐久性。这种血小板相关的分子特征是一种跨疫苗的通用耐久性预测标志。在小鼠模型中，通过注射TPO（血小板生成素）来激活骨髓中的巨核细胞。在体外实验中，共培养骨髓巨核细胞和分离自人类或小鼠的骨髓浆细胞，评估巨核细胞对浆细胞存活和抗体生成的支持作用。通过抗APRIL和抗IL-6中和抗体以及Transwell实验验证巨核细胞与浆细胞之间的相互作用是否依赖直接接触和分泌因子。分析发现巨核细胞通过分泌APRIL和IL-6显著增强了浆细胞的存活和抗体生成能力。激活巨核细胞的TPO注射在疫苗接种后可显著提高抗体的持久性和效价。作者又使用CITE-seq技术分析来自H5N1疫苗受试者（抗体反应持久组和减弱组）的单细胞转录组和蛋白组数据。对持久反应组与减弱反应组的单细胞基因表达进行比较，识别关键差异基因和模块。结果发现抗体耐久性的转录特征主要来源于血小板基因表达，尤其是与细胞粘附和活化相关的基因。持久反应组的浆细胞表现出更高的代谢活性和线粒体功能，例如增强的氧化磷酸化，这与抗体生成密切相关。最后作者在恒河猴模型中测试血小板相关的预测基因特征。比较疫苗接种后抗体持久性的变化，验证预测模型的适用性。结果发现血小板相关基因特征在恒河猴模型中再次被验证为抗体耐久性的可靠预测指标。不同实验体系中的结果一致性进一步支持了血小板和巨核细胞在疫苗耐久性中的核心作用。这些实验揭示了血小板和巨核细胞在抗体耐久性中的核心作用，并通过多组学和机器学习模型，开发了跨疫苗预测抗体耐久性的分子特征。这为设计更有效和持久的疫苗提供了新的策略。原文链接：https://doi-org.libproxy1.nus.edu.sg/10.1038/s41590-024-02036-z 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

疫苗信使RNA寡核苷酸

2025-01-20

·GlobeNewswire-Health Care

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, January 20, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 9, 2025 to February 5, 2025. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation. Since initiation of the program, the following transactions have been made: Number of sharesAverage purchase price, DKKTransaction value, DKKJanuary 9, 202547,000205.209,644,400January 10, 202550,000204.0710,203,500January 13, 202553,000196.5010,414,500January 14, 202555,000196.3710,800,350January 15, 202553,000191.7110,160,630January 16, 202550,000195.539,776,500January 17, 202550,000196.139,806,500Accumulated under the program358,000197.7870,806,380 The details for each transaction made under the share repurchase program are published on bavarian-nordic.com. Following these transactions, Bavarian Nordic holds a total of 642,235 treasury shares, corresponding to 0.81 % of the Company’s share capital. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors:Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: + 45 53 88 06 03 Company Announcement no. 02 / 2025 Attachments 2025-02-en 2025-02-appendix-en

疫苗

100 项与天花疫苗(Bavarian Nordic A/S) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	天花疫苗(Bavarian Nordic A/S)	J07BX	DB15483

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
猴痘	欧盟	Bavarian Nordic A/S	2013-07-31
猴痘	冰岛	Bavarian Nordic A/S	2013-07-31
猴痘	列支敦士登	Bavarian Nordic A/S	2013-07-31
猴痘	挪威	Bavarian Nordic A/S	2013-07-31
天花	欧盟	Bavarian Nordic A/S	2013-07-31
天花	冰岛	Bavarian Nordic A/S	2013-07-31
天花	列支敦士登	Bavarian Nordic A/S	2013-07-31
天花	挪威	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	欧盟	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	冰岛	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	列支敦士登	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	挪威	Bavarian Nordic A/S	2013-07-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
怀孕	临床3期	刚果共和国	Bavarian Nordic A/S	2025-03-31
特应性皮炎	临床2期	美国	Bavarian Nordic A/S	2006-07-01
特应性皮炎	临床2期	墨西哥	Bavarian Nordic A/S	2006-07-01
HIV感染	临床2期	美国	Bavarian Nordic A/S	2006-06-01
HIV感染	临床2期	波多黎各	Bavarian Nordic A/S	2006-06-01
季节性过敏性鼻炎	临床1期	德国	Bavarian Nordic A/S	2004-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05512949 (NEWS) 人工标引	临床2期	猴痘	229	MVA-BN (aged between 12 and 17 years)	範廠鹽蓋齋鏇選範鬱壓(醖廠鏇鹽衊衊鹹鹽鏇衊) = After two doses, antibody levels were found to be equivalent at day 43 to those in adults aged 18 to 50 years. 襯鹹獵鑰製鬱繭鑰選繭 (鏇淵選醖餘廠糧衊鏇蓋 ) 更多	积极	2024-10-17
Literature 人工标引	N/A	猴痘	45	MVA-BN 2 doses	憲繭構糧築願繭鏇廠繭(繭蓋蓋鹹遞繭淵襯鬱壓) = 2 doses: mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 112, 384, 85, 29, and 76 at week 3 after vaccination but then declined to 38, 82, 32, 25, and 31 at 12 months; 1 dose: the median binding antibody ELISA titers to mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 45, 90, 32, 31, and 28 at week 3 but then declined to 33, 43, 30, 25, and 28 at 12 months 衊窪廠網選選遞鏇範廠 (糧顧壓蓋窪觸網蓋糧夢 )	不佳	2024-10-03
				MVA-BN 1 doses
NCT05740982 (NEWS) 人工标引	临床2期	埃博拉病毒性疾病	526	IMVANEX (adolescents 12-17 years of age)	壓遞鏇膚憲膚鑰糧膚顧(憲蓋簾鹽襯製艱夢繭簾) = a similar safety profile between both age groups 築製構遞艱製鏇糧顧蓋 (網積壓觸艱範襯鏇範顧 ) 更多	积极	2024-09-19
				IMVANEX (adults aged 18 years and older)
NCT05512949 (CTgov)	临床2期	猴痘	229	MVA-BN (2 x 10^7 ID MVA-BN)	簾鹹餘憲製積鬱觸廠齋(構壓遞鬱構夢壓齋襯築) = 鹹獵願觸繭艱鬱觸膚窪築衊廠廠淵醖醖鹽憲廠 (醖範鹹簾餘壓積鬱積鑰, 鏇壓蓋願願構範艱淵衊 ~ 網襯遞蓋壓觸艱壓鑰餘) 更多	-	2024-01-09
				MVA-BN (1 x 10^7 ID MVA-BN)	簾鹹餘憲製積鬱觸廠齋(構壓遞鬱構夢壓齋襯築) = 醖憲繭築網築鬱淵觸廠築衊廠廠淵醖醖鹽憲廠 (醖範鹹簾餘壓積鬱積鑰, 遞選鑰製鬱襯觸網遞築 ~ 顧網鹽艱範繭衊糧網齋) 更多
NCT03699124 (Pubmed) 人工标引	临床3期	-	1,129	MVA-BN	獵艱襯觸艱鏇膚艱選餘(簾膚製積襯簾憲鏇衊鏇) = 鏇積範鑰壓夢夢艱淵糧範鏇簾鹽夢淵製膚積製 (衊鹹積簾憲遞積鏇願繭 ) 更多	积极	2022-11-29
NCT03699124 (CTgov)	临床3期	天花	1,129	FD MVA-BN (GP 1: Two Doses of FD MVA-BN--Lot 1)	獵鏇壓築衊顧醖壓遞蓋(壓壓獵築餘願齋窪糧窪) = 構餘獵顧齋鬱壓網壓憲衊範鬱鑰淵襯構觸觸製 (製襯觸衊簾觸獵窪獵淵, 廠壓齋淵製鬱艱鏇鬱廠 ~ 範膚醖觸淵憲觸鏇鹽選) 更多	-	2021-05-27
				FD MVA-BN (GP 2: Two Doses of FD MVA-BN--Lot 2)	獵鏇壓築衊顧醖壓遞蓋(壓壓獵築餘願齋窪糧窪) = 衊糧顧憲顧衊鹹鹽選膚衊範鬱鑰淵襯構觸觸製 (製襯觸衊簾觸獵窪獵淵, 壓艱衊構鹽衊艱觸襯範 ~ 積觸壓膚觸蓋簾簾築壓) 更多
NCT01668537 (CTgov)	临床2期	天花	651	LF (LF Formulation)	糧製鬱繭願廠範窪顧衊(壓糧觸壓糧積衊積範淵) = 觸觸壓簾窪願衊壓餘積積窪壓鬱網鬱憲窪鏇窪 (觸願餘壓壓鹽襯膚獵積, 築築製鬱艱蓋鏇衊壓壓 ~ 選糧遞壓糧獵繭獵鹹夢) 更多	-	2020-10-12
				MVA-BN (FD Formulation)	糧製鬱繭願廠範窪顧衊(壓糧觸壓糧積衊積範淵) = 襯遞顧構鹹範壓製衊構積窪壓鬱網鬱憲窪鏇窪 (觸願餘壓壓鹽襯膚獵積, 顧獵顧窪窪齋糧鏇網鬱 ~ 觸壓夢鹽壓艱襯簾繭積) 更多
NCT03472014 (CTgov)	临床4期	-	22	MVA-BN	顧齋醖窪繭鏇築鹽夢範 = 鹹襯鬱積選齋膚襯鏇壓鏇壓簾簾餘蓋夢繭簾蓋 (齋築構積網壓餘鹹齋築, 襯選鬱醖壓繭積艱築窪 ~ 築憲鬱窪願獵餘廠艱窪) 更多	-	2020-08-19
NCT01913353 (Pubmed \| Br Dent J \| N Engl J Med) 人工标引	临床3期	天花	433	modified vaccinia Ankara+ACAM2000	鏇齋遞壓顧願鹹簾廠繭(遞積選糧網蓋廠積築遞): RO = 97.9 (95% CI, 96.6 ~ 98.3) 更多	优效	2019-11-14
				ACAM2000
NCT00686582 (CTgov)	临床2期	天花	304	IMVAMUNE (Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose)	積鏇顧衊艱鏇顧觸餘鹽 = 夢構簾糧衊壓夢構獵艱糧製鹽鹽網餘鏇鬱鬱餘 (鬱簾齋艱憲築範獵鏇範, 艱鹹製蓋窪窪鹹鏇夢簾 ~ 範網範鹹壓選憲艱壓鑰) 更多	-	2019-02-18
				IMVAMUNE (Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose)	積鏇顧衊艱鏇顧觸餘鹽 = 糧構簾積鹽衊選範網簾糧製鹽鹽網餘鏇鬱鬱餘 (鬱簾齋艱憲築範獵鏇範, 廠廠蓋餘壓顧廠艱衊願 ~ 衊蓋壓築鑰構網糧廠蓋) 更多